• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

PROVENGE® (sipuleucel-T)

STN:  BL 125197
Proper Name: Autologous Cellular Immunotherapy
Tradename: PROVENGE® 
Manufacturer: Dendreon Corporation

Indication:

  • For the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. 
-

Supporting Documents

-
-

Related Information

  • Questions and Answers - Provenge [ARCHIVED]
  • FDA Online Label Repository
    Search this database for drug labeling and other information. The content has not been altered or verified by the FDA and may not be the labeling on currently distributed products or identical to the labeling that is approved.
-
 

Contact FDA

(800) 835-4709
(240) 402-8010
Consumer Affairs Branch (CBER)

Division of Communication and Consumer Affairs

Office of Communication, Outreach and Development

Food and Drug Administration

10903 New Hampshire Avenue

Building 71 Room 3103

Silver Spring, MD 20993-0002